Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Julie Dardare"'
Autor:
Andréa Witz, Julie Dardare, Aurélie Francois, Marie Husson, Marie Rouyer, Jessica Demange, Jean-Louis Merlin, Pauline Gilson, Alexandre Harlé
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Pancreatic cancer is one of the most aggressive diseases with a very poor outcome. Olaparib, a PARP inhibitor, as maintenance therapy showed benefits in patients with metastatic pancreatic adenocarcinoma bearing germline BRCA1/2 mutations. H
Externí odkaz:
https://doaj.org/article/9880545833874a948d6b63b019ad89aa
Autor:
Pauline Gilson, Celso Pouget, Richard Belmonte, Smahane Fadil, Jessica Demange, Marie Rouyer, Julien Lacour, Margaux Betz, Julie Dardare, Andréa Witz, Jean-Louis Merlin, Alexandre Harlé
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract Gene fusions and MET exon skipping drive oncogenesis in 8–9% and 3% of non-small cell lung cancers (NSCLC) respectively. Their detection are essential for the management of patients since they confer sensitivity to specific targeted therap
Externí odkaz:
https://doaj.org/article/20406c264bfb4ec3b46fea9ad92a6877
Autor:
Margaux Betz, Vincent Massard, Pauline Gilson, Andréa Witz, Julie Dardare, Alexandre Harlé, Jean-Louis Merlin
Publikováno v:
Cancers, Vol 15, Iss 21, p 5169 (2023)
The predominant forms of breast cancer (BC) are hormone receptor-positive (HR+) tumors characterized by the expression of estrogen receptors (ERs) and/or progesterone receptors (PRs). Patients with HR+ tumors can benefit from endocrine therapy (ET).
Externí odkaz:
https://doaj.org/article/baba77557d4a4305b99fd1ab01e3d623
Autor:
Julie Dardare, Andréa Witz, Margaux Betz, Aurélie Francois, Morgane Meras, Laureline Lamy, Aurélien Lambert, Stéphanie Grandemange, Marie Husson, Marie Rouyer, Jessica Demange, Jean-Louis Merlin, Alexandre Harlé, Pauline Gilson
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionDamage specific DNA binding protein 2 (DDB2) is an UV-indiced DNA damage recognition factor and regulator of cancer development and progression. DDB2 has dual roles in several cancers, either as an oncogene or as a tumor suppressor gene,
Externí odkaz:
https://doaj.org/article/a3ca4813d8d344d2a4dc2b42439f7ed6
Autor:
Julie Dardare, Andréa Witz, Jean-Louis Merlin, Agathe Bochnakian, Paul Toussaint, Pauline Gilson, Alexandre Harlé
Publikováno v:
Pharmaceuticals, Vol 14, Iss 8, p 740 (2021)
Pancreatic ductal adenocarcinoma (PDAC) is one of the malignancies with the worst prognosis despite a decade of efforts. Up to eighty percent of patients are managed at late stages with metastatic disease, in part due to a lack of diagnosis. The effe
Externí odkaz:
https://doaj.org/article/48ae2811044f4d12b22f18372d07b9c3
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 10, p 3534 (2020)
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death worldwide. PDAC is an aggressive disease with an 11-month median overall survival and a five-year survival of less than 5%. Incidence of PDAC is constantly increasing
Externí odkaz:
https://doaj.org/article/fb76c6b65eb34c529f725aa58152c9f4
Autor:
Andréa Witz, Julie Dardare, Aurélie Francois, Marie Husson, Marie Rouyer, Jessica Demange, Pauline Gilson, Jean-Louis Merlin, Alexandre Harlé
Background: Pancreatic cancer is one of the most aggressive diseases with a very poor outcome. Olaparib, a PARP inhibitor, as maintenance therapy showed benefits in patients with metastatic pancreatic adenocarcinoma bearing germline BRCA1/2 mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6550052b6feebaccffa78d652a7a346
https://doi.org/10.21203/rs.3.rs-1439273/v1
https://doi.org/10.21203/rs.3.rs-1439273/v1
Autor:
Pauline Gilson, Paul Toussaint, Julie Dardare, Agathe Bochnakian, Jean-Louis Merlin, Alexandre Harlé, Andréa Witz
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 740, p 740 (2021)
Pharmaceuticals, MDPI, 2021, 14 (8), pp.740. ⟨10.3390/ph14080740⟩
Pharmaceuticals, Vol 14, Iss 740, p 740 (2021)
Pharmaceuticals, MDPI, 2021, 14 (8), pp.740. ⟨10.3390/ph14080740⟩
International audience; Pancreatic ductal adenocarcinoma (PDAC) is one of the malignancies with the worst prognosis despite a decade of efforts. Up to eighty percent of patients are managed at late stages with metastatic disease, in part due to a lac
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 3534, p 3534 (2020)
International Journal of Molecular Sciences
International Journal of Molecular Sciences, MDPI, 2020, 21 (10), pp.3534. ⟨10.3390/ijms21103534⟩
International Journal of Molecular Sciences
International Journal of Molecular Sciences, MDPI, 2020, 21 (10), pp.3534. ⟨10.3390/ijms21103534⟩
International audience; Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death worldwide. PDAC is an aggressive disease with an 11-month median overall survival and a five-year survival of less than 5%. Incidence of PDAC
Autor:
Pauline Gilson, Marie Husson, J-L. Merlin, A. Francois, Julie Dardare, Alexandre Harlé, Andréa Witz
Publikováno v:
Annals of Oncology. 32:S1356